Kern Capital
Deals on record
1
Common Fundraising Type
Series B
Latigo Biotherapeutics
Non-opioid • Pain treatments
Latigo Biotherapeutics develops non-opioid pain treatments, focusing on selective Nav1.8 inhibitors.
Deals on record
Common Fundraising Type
Non-opioid • Pain treatments
Latigo Biotherapeutics develops non-opioid pain treatments, focusing on selective Nav1.8 inhibitors.